Blissel®

A formulation for the treatment of vaginal atrophy which delivers proven clinical efficacy2,3, high patient satisfaction3 and negligible systemic exposure after 21 days3. For women with urogenital symptoms, offer low-dose vaginal oestrogen first-line (NICE CKS).1

A formulation for the treatment of vaginal atrophy
Efficacy

Significant improvement in the core symptoms of vaginal dryness

Treatment posology and cost
A formulation for the treatment of vaginal atrophy
  • An innovative mucoadhesive, clear gel for the local treatment of vaginal atrophy2
  • Strongly hydrating properties ensure treatment related relief of symptoms3
  • Over 70% improvement in the signs and symptoms of vaginal atrophy3
  • Low concentration of estriol (0.005% w/w estriol)3
  • 88% of women expressed a positive opinion for cleanliness, leakage, ease of administration3

A drop of bliss that delivers...

A formulation for the treatment of vaginal atrophy
Significant improvement in Maturation Value* at both 3 weeks and 12 weeks (p<0.001)3
After 3 weeks treatment with Blissel® vaginal gel:

  • Vaginal Dryness improved or cured in 95% of women
    (versus 67% with placebo, p<0.001) 3
  • Dyspareunia improved or cured in 88% of women
    (versus 69% with placebo, p=0.009)3
  • Vaginal Pruritus improved or cured in 88% of women
    (versus 64% with placebo, p=0.013)3

Improves Quality of Life and Sexual Health in postmenopausal women4

Treatment posology and cost 2,5

Initial treatment (new patients)

One application/day during the first 3 weeks, preferably at bed time

Maintenance treatment

One application twice a week, preferably at bed time

Blissel is 10% less expensive than Vagifem® in maintenance treatment5
References

1. NICE, CKS, Menopause (Accessed February 2022)

2. Blissel SmPC (Accessed February 2022)

3. Cano et al. 2012

4. Caruso et al. 2015

5. British National Formulary (Accessed February 2022)

 

*Maturation Value was obtained from cellular count of vaginal smears